Biotech company Nuage Therapeutics, member of CATALONIA.HEALTH, has announced the appointment of Stuart Hughes as Chief Executive Officer and Vanessa Malier as Chair of the Board of Directors. Hughes will succeed outgoing and founding CEO, Judit Anido, who is assisting with the leadership transition.

Nuage has developed a set of tools that enables the reconstitution of intrinsically disordered proteins (IDPs) in a secondary-structured form that renders them amenable to small molecule drug discovery. This has enabled the company to unlock a wide range of previously intractable but important drug targets with a robust human biological basis for therapeutic intervention.

Stuart Hughes has broad R&D leadership experience in a range of settings having worked in drug discovery across multiple therapeutic areas. He joins Nuage from Pathios Therapeutics, an immuno-oncology company where he served as CEO and where he built the company from an initial seed investment to a clinical-stage organisation. He has a MSc in Electrical & Electronic Engineering and a PhD in Neuroscience from Cardiff University.

Vanessa Malier is board member and advisor to biotech, venture capital and private equity firms. She previously spent 10 years as Managing Partner at Kurma Partners and was instrumental in the scale-up of the firm, fund raising Biofund III and the growth fund, completing the deal with Eurazeo and investing in portfolio companies. She graduated from Pasteur Institute in Immunology and Ecole Normale Supérieure in Biology and Biochemistry.

Stuart Hughes, new CEO of Nuage Therapeutics, mentioned: “Nuage possesses a highly differentiated suite of technologies that enables the capture of ‘disordered’ proteins in a form that is amenable to small molecule screening and profiling. I believe Nuage represents a game-changing advance in drug discovery and precision medicine, especially where targets have previously been considered undruggable. Allied to a highly skilled team and the support of top-tier investors, Nuage is ideally positioned for growth and success. I look forward to getting started.”

More information